Standard denial management works because the rules are known. A physician’s office submits a claim for an established procedure, the payer checks it against existing policy, and any denial follows a predictable pattern with a predictable fix.
New and emerging medical technologies don’t get that luxury.
When a device launches without an established payer coverage policy, without consistent prior authorization criteria, and without a shared clinical framework between the physician and the insurer, every authorization and every claim enters unpredictable territory. This is what makes denials management for medical devices a fundamentally different discipline. Denials follow not because the technology doesn’t work, but because the payer system hasn’t built the infrastructure to evaluate it yet.
JDL Access was founded in 2021 specifically to navigate that gap, bringing the specialized expertise that new device reimbursement demands.
What Denials Management for Innovative Medical Technologies Typically Looks Like
When a physician’s office or a facility preauthorizes or bills for an established procedure, the payer typically has precedent to draw on: known CPT/HCPCS codes, defined medical policy, and a record of prior claims.
Medical device denials management for new or novel technologies starts from a very different position.
- A newly launched device may not yet have a permanent code.
- The payer may not have published a coverage policy at all, leaving front-line reviewers to make judgment calls with limited guidance.
- The staff submitting the authorization or claim may be unfamiliar with the technology’s clinical use case, which increases the odds of a denial simply because the submission doesn’t clearly demonstrate why the device was necessary.
In this environment, denials management is a matter of building the case for a technology payers haven’t fully evaluated yet. Effective denials management for medical devices therefore starts before a claim is ever denied, with the right documentation, coding and payer-specific requirements identified upfront.
Why New Medical Device Denials Operate on Different Rules
Several structural realities separate innovative device-related denials from standard denials:
The Absence of Established Medical Policy
Many payers simply haven’t written formal policy for newer devices. Without a published medical policy, reviewers fall back on general coverage criteria that may not map well to the device’s actual clinical application.
This is one of the defining medical device reimbursement challenges manufacturers face: there is no rulebook to follow, so every authorization or claim risks inconsistent treatment from payer to payer – and sometimes reviewer to reviewer within the same payer.
Medical Necessity Denials: When the Patient Doesn’t Meet Established Criteria
Not every denial stems from a policy vacuum. Many payers do have a written medical policy for a given device, and that policy is favorable: the technology is covered when specific clinical criteria are met.
A medical necessity denial in this context means the payer reviewed the individual patient’s chart and determined the documentation didn’t demonstrate that those criteria were satisfied. This is a clinical dispute that calls for a specific kind of appeal:
- additional clinical documentation
- supporting literature
- peer-to-peer conversation between the treating physician and the payer’s medical director
This is all to make the case that the patient does, in fact, meet the established criteria.
Experimental or Investigational Denials: A Separate Category That Requires a Different Appeal
A second, and often more difficult, category of denial has nothing to do with an individual patient’s chart. Some payers write medical policy that classifies a device outright as experimental or investigational, meaning the payer has concluded that there is insufficient evidence to cover it in general, regardless of clinical presentation.
This determination is typically driven by one of two factors:
- the device is new enough that the payer’s evidence review hasn’t caught up
- the device carries a non-standard billing code (unlisted or Category III), which many payers treat as a signal that the technology is unproven.
Overturning an experimental or investigational denial requires a different appeal strategy than a standard medical necessity appeal. It has to address the payer’s evidentiary threshold directly with the following:
- clinical literature
- comparative outcomes data
- an explanation of what a Category III code does and doesn’t indicate about a device’s safety and efficacy (where applicable)
Prior Authorization Requirements Vary Widely by Payer
There’s no uniform standard for prior authorization support across payers when it comes to novel devices. For example:
- One payer may require extensive documentation packages before a procedure even occurs
- Another may have no formal prior authorization pathway at all, creating ambiguity about what “approval” looks like.
Without dedicated denials management processes built around this variability, it is difficult to overcome.
What Effective Medical Device Denials Management Actually Requires
Medical device reimbursement support can’t be treated as a transactional service, but rather it has to be built as an ongoing, coordinated function.
End-to-End Case Management vs. Transactional Authorization or Billing Support
Traditional preauthorization and billing support tends to operate claim-by-claim: authorize this procedure, bill this code, appeal this denial. Effective coding and billing compliance for medical devices requires true case management – following a patient’s access journey from initial prior authorization through claim submission and then, if needed, through any denials. Consistent clinical and coding expertise must be applied at every step.
That means:
- Proactively identifying which payers require prior authorization for a given device, and what documentation they expect;
- Conducting device coding validation before submission;
- Building payer-specific denial and appeal strategies; and
- Ensuring reimbursement support for providers and their staff.
How JDL Access Approaches Medical Device Denials Management
JDL Access was built around the recognition that denials management for medical devices requires specialized infrastructure. Our approach combines coding validation and support with proactive preauthorization support. When denials do occur, our team applies payer denials management strategies grounded in clinical evidence and a clear understanding of each payer’s evolving policy landscape.
Providers and device manufacturers working with JDL Access have access to dedicated reimbursement support services, including a reimbursement support line and/or case management team, staffed by people who know the specific technology and the specific payer landscape it’s moving through.
That continuity turns denials management from a reactive approach into a genuine advantage, helping innovative technologies reach the patients who need them instead of getting lost in payer red tape.
